MA27062A1 - Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliques - Google Patents
Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliquesInfo
- Publication number
- MA27062A1 MA27062A1 MA27550A MA27550A MA27062A1 MA 27062 A1 MA27062 A1 MA 27062A1 MA 27550 A MA27550 A MA 27550A MA 27550 A MA27550 A MA 27550A MA 27062 A1 MA27062 A1 MA 27062A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- dihydro
- triazolo
- pyridines
- inhalation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 12 Septembre 2001 0122031.8 Voir en annexe le titre de l'invention et le texte de l'abrégé Compositions pour inhalation, comprenant des 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4, 3-(alpha)]pyridines tricycliques La présente invention concerne une formulation à inhaler comprenant un composé choisi dans une catégorie particulière de 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-(alpha)]pyridines, qui est capable de délivrer le composé sous forme de fines particules solides au poumon, et l'utilisation d'une telle formulation dans le traitement de certaines maladies telles que des maladies respiratoires. Au moyen de telles formulations, il est possible de supprimer la réponse de toux indésirable associée à l'utilisation de ces composés dans des inhalateurs à doses mesurées de solution, réponse qui peut empêcher l'administration d'une dose therapeutiquement efficace et, à long terme, entraver l'observance du patient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0122031.8A GB0122031D0 (en) | 2001-09-12 | 2001-09-12 | Use of pde4 inhibitors in a dry powder inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27062A1 true MA27062A1 (fr) | 2004-12-20 |
Family
ID=9921954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27550A MA27062A1 (fr) | 2001-09-12 | 2004-02-26 | Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliques |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20030064031A1 (fr) |
| EP (1) | EP1427414A1 (fr) |
| JP (1) | JP2005505560A (fr) |
| KR (1) | KR20040036940A (fr) |
| CN (1) | CN1553801A (fr) |
| AP (2) | AP2002002624A0 (fr) |
| AR (2) | AR036473A1 (fr) |
| BG (1) | BG108569A (fr) |
| BR (1) | BR0212449A (fr) |
| CA (1) | CA2457717A1 (fr) |
| CZ (1) | CZ2004310A3 (fr) |
| EA (1) | EA006742B1 (fr) |
| EC (1) | ECSP045018A (fr) |
| EE (1) | EE200400078A (fr) |
| GB (1) | GB0122031D0 (fr) |
| HN (2) | HN2002000253A (fr) |
| HR (1) | HRP20040162A2 (fr) |
| HU (1) | HUP0401890A3 (fr) |
| IL (1) | IL160380A0 (fr) |
| IS (1) | IS7151A (fr) |
| MA (1) | MA27062A1 (fr) |
| MX (1) | MXPA04002354A (fr) |
| NO (1) | NO20041011L (fr) |
| NZ (1) | NZ530929A (fr) |
| OA (1) | OA12660A (fr) |
| PA (2) | PA8554701A1 (fr) |
| PE (2) | PE20030443A1 (fr) |
| PL (1) | PL368736A1 (fr) |
| PY (2) | PY0221504A (fr) |
| SK (1) | SK1272004A3 (fr) |
| SV (2) | SV2004001227A (fr) |
| TN (1) | TNSN04040A1 (fr) |
| TW (1) | TW200602054A (fr) |
| WO (2) | WO2003022279A1 (fr) |
| ZA (1) | ZA200401002B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| MXPA05007156A (es) * | 2002-12-31 | 2005-09-21 | Nektar Therapeutics | Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas. |
| GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| CA2623882A1 (fr) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Formulation de poudre aerosol comprenant un lactose tamise |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| TR200909788A2 (tr) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu |
| CA2900302C (fr) | 2013-02-19 | 2018-07-03 | Pfizer Inc. | Composes d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections |
| KR20150076005A (ko) | 2013-12-26 | 2015-07-06 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| WO2016012896A1 (fr) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Composés de pyrazolopyrimidine |
| CR20170035A (es) | 2014-08-06 | 2017-04-28 | Pfizer | Compuestos de imidazopiridazina |
| HUE055527T2 (hu) * | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69525978T2 (de) * | 1995-06-06 | 2002-12-19 | Pfizer | Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19835346A1 (de) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
-
2001
- 2001-09-12 GB GBGB0122031.8A patent/GB0122031D0/en not_active Ceased
-
2002
- 2002-09-02 EA EA200400301A patent/EA006742B1/ru not_active IP Right Cessation
- 2002-09-02 WO PCT/IB2002/003598 patent/WO2003022279A1/fr not_active Ceased
- 2002-09-02 IL IL16038002A patent/IL160380A0/xx unknown
- 2002-09-02 NZ NZ530929A patent/NZ530929A/en unknown
- 2002-09-02 WO PCT/IB2002/003599 patent/WO2003022275A1/fr not_active Ceased
- 2002-09-02 EE EEP200400078A patent/EE200400078A/xx unknown
- 2002-09-02 PL PL02368736A patent/PL368736A1/xx not_active Application Discontinuation
- 2002-09-02 CN CNA028178874A patent/CN1553801A/zh active Pending
- 2002-09-02 HR HR20040162A patent/HRP20040162A2/xx not_active Application Discontinuation
- 2002-09-02 MX MXPA04002354A patent/MXPA04002354A/es not_active Application Discontinuation
- 2002-09-02 OA OA1200400071A patent/OA12660A/en unknown
- 2002-09-02 SK SK127-2004A patent/SK1272004A3/sk not_active Application Discontinuation
- 2002-09-02 CA CA002457717A patent/CA2457717A1/fr not_active Abandoned
- 2002-09-02 JP JP2003526404A patent/JP2005505560A/ja not_active Withdrawn
- 2002-09-02 HU HU0401890A patent/HUP0401890A3/hu unknown
- 2002-09-02 CZ CZ2004310A patent/CZ2004310A3/cs unknown
- 2002-09-02 KR KR10-2004-7003619A patent/KR20040036940A/ko not_active Abandoned
- 2002-09-02 BR BR0212449-1A patent/BR0212449A/pt not_active IP Right Cessation
- 2002-09-02 EP EP02767763A patent/EP1427414A1/fr not_active Withdrawn
- 2002-09-04 PY PY200200221504A patent/PY0221504A/es unknown
- 2002-09-04 PY PY200200221503A patent/PY0221503A/es unknown
- 2002-09-05 US US10/236,551 patent/US20030064031A1/en not_active Abandoned
- 2002-09-05 US US10/236,228 patent/US20030064034A1/en not_active Abandoned
- 2002-09-10 PE PE2002000894A patent/PE20030443A1/es not_active Application Discontinuation
- 2002-09-10 PE PE2002000893A patent/PE20030509A1/es not_active Application Discontinuation
- 2002-09-10 AR ARP020103426A patent/AR036473A1/es unknown
- 2002-09-10 AR ARP020103427A patent/AR036474A1/es unknown
- 2002-09-11 TW TW094130352A patent/TW200602054A/zh unknown
- 2002-09-11 HN HN2002000253A patent/HN2002000253A/es unknown
- 2002-09-12 PA PA20028554701A patent/PA8554701A1/es unknown
- 2002-09-12 SV SV2002001227A patent/SV2004001227A/es not_active Application Discontinuation
- 2002-09-12 PA PA20028554601A patent/PA8554601A1/es unknown
- 2002-09-12 SV SV2002001226A patent/SV2004001226A/es not_active Application Discontinuation
- 2002-09-12 AP APAP/P/2002/002624A patent/AP2002002624A0/en unknown
- 2002-09-12 AP APAP/P/2002/002623A patent/AP2002002623A0/en unknown
- 2002-10-11 HN HN2002000254A patent/HN2002000254A/es unknown
-
2004
- 2004-02-06 ZA ZA200401002A patent/ZA200401002B/en unknown
- 2004-02-09 BG BG108569A patent/BG108569A/bg unknown
- 2004-02-13 IS IS7151A patent/IS7151A/is unknown
- 2004-02-26 MA MA27550A patent/MA27062A1/fr unknown
- 2004-03-10 TN TNP2004000040A patent/TNSN04040A1/fr unknown
- 2004-03-10 NO NO20041011A patent/NO20041011L/no not_active Application Discontinuation
- 2004-03-12 EC EC2004005018A patent/ECSP045018A/es unknown
-
2005
- 2005-06-13 US US11/152,741 patent/US20050232871A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27062A1 (fr) | Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliques | |
| WO2003039436A3 (fr) | Compositions pharmaceutiques contenant de l'oxybutine | |
| MA26892A1 (fr) | Formulations pharmaceutiques sous forme de comprimes pour inhalateurs a parer | |
| YU56600A (sh) | Uređaj za raznošenje aktivnog agensa u pluća pacijenta | |
| BE1003053A3 (fr) | Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. | |
| WO2005065069A3 (fr) | Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer | |
| IL139229A0 (en) | Drug delivery system comprising a tightly compacted solid medicament stock | |
| BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
| ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| MXPA04004393A (es) | Nuevos usos para agentes terapeuticos anti-malarios. | |
| CA2277365A1 (fr) | Traitement de la sclerose en plaques par l'ingestion ou l'inhalation de copolymere-1 | |
| EP1358177B1 (fr) | Traitement de troubles affectifs par l'action combinee d'un agoniste du recepteur nicotinique et d'une substance monoaminergique | |
| AU2002314102A1 (en) | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways | |
| JP2012255039A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| MXPA05009629A (es) | Composiciones que contienen trospio. | |
| KR20070020036A (ko) | 수면 장애를 위한 조성물 | |
| HRP20241022T1 (hr) | Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos) | |
| WO1997022354A3 (fr) | Emploi d'un medicament et utilisation d'un melange de substances pour la production d'un medicament | |
| MXPA04010860A (es) | Composiciones terapeuticas de 1,2,3,6-tetrahidropirimidin-2-ona y metodos para usarla. | |
| KR860003018A (ko) | 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법 | |
| KR20050085104A (ko) | 로플루미래스트와 포르모테롤을 포함하는 신규한상승작용성 조합물 | |
| WO2010025505A1 (fr) | Analgésie par administration transmuqueuse | |
| AU2003288169B8 (en) | Synergistic combination comprising roflumilast and (R,R) -formoterol | |
| JP2002541190A (ja) | 気分障害治療用医薬を製造するためのオサネタントの使用 | |
| HUP9900521A2 (hu) | Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására |